Background: Utilization of chemotherapy for patients with muscle-invasive bladder cancer (MIBC) is low. In earlier qualitative work we used the Theoretical Domains Framework (TDF) to determine barriers and enablers of chemotherapy use. In this project we aimed to determine the prevalence of these barriers and enablers in Canadian physicians. Methods: Practicing Canadian urologists, medical oncologists (MOs) and radiation oncologists (ROs) participated in a specialty-specific web-based quantitative survey to assess potential barriers and enablers to chemotherapy use. Survey questions were developed that were thematically mapped to TDF domains. Logistic regression was used to identify TDF domains associated with high referral/use of chemotherapy. Results: 110 urologists, 47 MOs and 43 ROs completed the survey; response rates were 20%, 35% and 31% respectively. The mean reported survival gain associated with neoadjuvant chemotherapy (NACT) was 9%, 8%, and 7% for urologists, MOs, and ROs respectively. Among participating urologists, the TDF domains 'social and professional role' (OR = 16.5, 95% CI 4.6-59.2), 'social influences' (OR = 5.7, 95% CI 2.4-13.4) 'beliefs about consequences' (OR = 4.9, 95% CI 1.8-13.3) and 'memory, attention and decision-making' (OR = 0.50, 95% CI 0.27-0.91) were associated with MO referral rates. Among MOs, the TDF domains 'behavioural regulation', 'social influences', and 'social and professional role' were associated with greater use of chemotherapy (p < 0.05). No TDF domains were associated with RO referral to MO. Conclusions: We have identified several factors associated with referral/use of chemotherapy for MIBC. Optimization of multidisciplinary patient care needs to be considered when designing future interventions to close the gap between evidence and practice.
INTRODUCTION
International guidelines recommend neoadjuvant chemotherapy (NACT) for patients with muscleinvasive bladder cancer (MIBC) [1] [2] [3] ; emerging evidence suggests that adjuvant chemotherapy (ACT) provides comparable benefit [4, 5] . We have recently described practice patterns in Ontario, Canada [6, 7] . Only 6% and 22% of patients in Ontario received NACT or ACT during 1994-2008, respectively; 16% and 39% of patients were referred to MO for consideration of NACT/ACT. Similar findings have been described elsewhere [8] [9] [10] [11] . These data identify upstream barriers at the urologist and downstream at the MO.
Limited literature exists that identifies barriers and enablers to chemotherapy use for bladder cancer with most studies only describing self-reported practice patterns [7, [12] [13] [14] . A recent survey of 125 urologic oncologists found that the strongest patient factors associated with use of NACT was clinical T3/4 disease [15] . The same study also found that surgeons who work at centres where medical oncologists are strong proponents of NACT are more likely to discuss this treatment option with patients. We recently undertook a qualitative study using a knowledge translation (KT) framework to identify knowledge, attitudes and beliefs among urologists, MOs and radiation oncologists (ROs) about NACT/ACT (In Press, Can Urol Assoc J). The predominant enablers to the use of chemotherapy included: the presence of chemotherapy 'champions', routine referral to MO, and system-level factors that optimize multidisciplinary care. The predominant barriers included: a lack of confidence in the magnitude of benefit associated with NACT/ACT and inadequate multidisciplinary collaboration.
Use of a knowledge translation (KT) conceptual framework can guide future intervention studies [16, 17] . The Theoretical Domains Framework (TDF) is a comprehensive framework to identify barriers and enablers of implementing evidence into practice. The TDF can facilitate design of KT interventions as it offers broad coverage of potential change pathways [18] .
We undertook this quantitative study to determine the prevalence of barriers and enablers among practicing urologists, MOs and ROs. Barriers and enablers identified within the relevant theoretical domains can subsequently be mapped to appropriate implementation interventions in an effort to increase chemotherapy utilization.
METHODS

Study design and participants
Results from an earlier qualitative study (In Press, Can Urol Assoc J) informed the development of a cross-sectional survey for the three specialist groups. All practicing urologists, MOs and ROs who treat patients with bladder cancer in Canada were invited to participate in the electronic survey (June 2016). The survey was distributed to all Canadian urologists and MOs/ROs that treat bladder cancer. The survey was distributed electronically using Fluid Surveys©-software. A modified approach of Dillman's Total Design Method [19] was used to maximize response rates. The study was approved by the Research Ethics Board of Queen's University.
Survey design and content
Survey design was based on thematic analysis of our recently completed qualitative study. Question development was based on targeted health behaviours: (1) Are urologists referring patients to MO for NACT/ ACT?; (2) Are MOs treating patients with NACT/ACT?; and (3) Are ROs referring patients to MO for NACT/ACT if not already done by urology? The surveys included questions informed by domains of the TDF [17] (Appendix 1) pertaining to (a) the knowledge, attitudes and beliefs of the clinicians about referral/use of NACT/ACT; and (b) the potential barriers and enablers of chemotherapy delivery. Responses to the majority of survey questions were in the form of categorical (yes/no; multiple choice) and ordinal variables (5-point Likert scale).
Questions were developed for each TDF domain. TDF domains are not mutually exclusive and thus a survey question may be mapped to more than one relevant TDF domain. Responses to ordinal survey questions were collapsed into three categories for analysis purposes: strongly disagree/disagree, neutral, strongly agree/agree. In addition, a composite summary mean score of all questions relevant to each of the identified TDF domains was created for univariate analysis [20, 21] . Higher scores are more conducive to achieving the targeted health behaviours (i.e. increased referral/use of NACT/ACT). Participants were excluded from the summary score for a given TDF domain if there were missing values on any questions within that domain. This approach was chosen since we had few study respondents with missing values (16/200 had ≥1 missing value) and we could not assume responses were missing at random [20, 21] .
The surveys also included questions about contraindications for chemotherapy and the presentation of a hypothetical case. Open-ended survey questions were used to ask participants about the greatest achievements and challenges in delivering chemotherapy.
The surveys were developed by a multidisciplinary team with expertise in the treatment of bladder cancer and expertise in survey methodology/implementation science.
Statistical analysis
We used the following questions to classify respondents as low or high adopters of NACT/ACT: Urologists -'Of the last 10 ' . Respondents whose reported values were greater than or equal to the median were classified as high adopters. Logistic regression was used to identify TDF domains associated with high adoption of NACT/ACT referral/use in practice. Results were considered statistically significant at p-value < 0.05. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Study participants
Survey response rates were 20% for urologists (110/562), 36% for MOs (47/131), and 31% for ROs (43/139). The proportion of respondents who treated >10 MIBC patients/year were 34% (37/110 urologists), 47% (22/47 MOs), and 28% (12/43 ROs).
Case scenario and survival estimates
Survival estimates for a hypothetical case of a 60 year old man with clinical T3N0 MIBC are shown in Table 1 . Mean overall survival at 5 years with cystectomy alone was 53%, 61% with NACT and 56% with ACT. However, as shown in Fig. 1 there is substantial variation within each specialty. Urologists, MOs and ROs reported a mean 9%, 8%, and 7% survival gain with NACT respectively; corresponding mean survival gains with ACT were 2%, 4%, and 4% respectively.
Identified barriers and enablers to NACT/ACT referral/use
Urologists reported referring a median of 9/10 patients to MO to discuss NACT/ACT. MOs reported treating a median of 7/10 patients referred for NACT/ ACT. ROs reported that a median of 3/10 MIBC patients seen were not already referred to MO by urology; a median of 2/3 patients were subsequently referred to MO. Univariate associations between TDF summary domain scores and referral/use of NACT/ACT are found in Table 2 . A summary of specialist-specific survey questions and responses organized by TDF domain can be found in Appendices 2-4.
Behaviour 1: Are urologists referring MIBC patients to MO for NACT/ ACT?
TDF domains 'beliefs about consequences' (OR = 4.9, 95% CI 1.8-13.3), 'social and professional role' (OR = 16.5, 95% CI 4.6-59.2) and 'social influences' (OR = 5.7, 95% CI 2.4-13.4) were all associated with higher rates of referral to MO. Within these domains we highlight pertinent questions and responses. 'Beliefs about consequences': 89% (94/106) felt confident in the evidence supporting NACT, 82% (87/106) felt the magnitude of benefit associated with NACT is important, and 25% (27/106) were concerned about NACT delaying surgery. 'Social and professional role': 46% (45/97) felt it was their responsibility to select which patients are eligible for chemotherapy and only refer those patients. 'Social influences': 77% (74/96) reported that patients are generally accepting of chemotherapy. The TDF domain 'memory, attention and decision making' was inversely associated with referral to MO (OR = 0.50, 95%CI 0.27-0.91). Forty-four percent of urologists (45/103) felt confident in determining who was a candidate for chemotherapy.
Behaviour 2: Are MOs treating MIBC patients with NACT/ACT?
TDF domains 'social and professional role' (OR = 4.9, 95% CI 1.1-22.0), 'social influences' (OR = 6.6, 95% CI 1.5-28.6) and 'behavioural regulation' (OR = 12.2, 95% CI 2.0-75.6) were associated with increased use of NACT/ACT (Table 3) . 'Social Among ROs, no TDF domains were associated with increased referral of MIBC patients to MO for chemotherapy consultation (Table 2 ). This is likely explained by the fact that, in this study, very few patients (3/10) seen by ROs had not already been referred to MO for chemotherapy consultation.
Contraindications to chemotherapy
Reported contraindications to chemotherapy are shown in Table 3 . Poor performance status (>ECOG 2), renal insufficiency, and peripheral neuropathy were reported by a majority of respondents as contraindications to NACT/ACT.
System-level barriers and enablers in relation to referral/use of NACT/ACT
The TDF domain 'environmental context and resources' emerged as a common theme in the open-response question about the greatest achievements/challenges in delivering chemotherapy. Common themes included access to urologists/MOs with genitourinary cancer expertise, multidisciplinary bladder clinics (MBC) and case conferences (MCC); availability of nurse navigator; communication between urology and MO; and accessibility of operating room time. A substantial majority of respondents felt that having MCCs, MBCs, and a mandatory MO referral policy contributed to greater use of NACT/ACT at their centre (Table 4) .
Do provider beliefs guide practice?
The median magnitude of benefit (i.e. absolute improvement in 5 year OS) associated with NACT was 5%. Providers who reported an estimated effect size of >5% were more likely to be refer/deliver chemotherapy compared to providers who reported estimated effect sizes of <5% (67% vs 46%, p = 0.003). Twenty-three percent of all respondents strongly agreed that magnitude of survival benefit associated with NACT is important; 62% of these providers were "adopters" of chemotherapy compared to 54% of providers who did not strongly agree (p = 0.334).
DISCUSSION
This survey explored knowledge, attitudes, and beliefs of urologists, MOs, and ROs in Canada regarding the utilization of NACT/ACT for muscle-invasive bladder cancer. The survey questions were designed using a KT framework and guided by our earlier qualitative work in semi-structured interviews. Among urologists and MOs the TDF domains 'social and professional role' and 'social influences' were associated with higher referral/use chemotherapy. Common enablers within these domains relate to having local champions who advocate for use of NACT/ACT, routine referral from urology to MO, and the belief that patients were generally accepting of chemotherapy. Conversely, a lack of local champions, and a perception among urologists that MOs do not treat the majority of referred patients with chemotherapy were identified as barriers. A proportion of participating urologists did not feel that it was their responsibility to refer all patients to MO and would only refer patients they deemed eligible for chemotherapy. Factors related to 'environmental context and resources' were consistently identified in free-text responses as primary barriers/enablers to use of chemotherapy but this domain was not found to be associated with referral/use of NACT/ACT in the univariate model. Those who did practice in settings with MBCs, nurse navigators, and mandatory MO referral felt that these system-level resources were increased utilization of NACT/ACT.
Our study also highlights a substantial disconnect between outcomes anticipated by clinicians and outcomes achieved in routine practice. The five year overall survival estimates (53% with cystectomy and 61% with NACT/cystectomy) are substantially higher than outcomes we have previously reported in the general population of Ontario (29% and 25% respectively) [6] . Moreover, our data show tremendous variation in survival estimates between providers even within the same specialty. This gap between expected and actual outcomes is an area that warrants knowledge translation efforts to ensure that clinicians and patients have a clear understanding of disease prognosis. Consistent with prior literature in lung cancer, we also found that provider beliefs are associated with adoption of chemotherapy for bladder cancer [22] .
To our knowledge, this is the first study to evaluate clinician perceived barriers and enablers to chemotherapy for bladder cancer using a KT framework. In seeking to identify and determine the prevalence of potential barriers and enablers influencing practice, use of the TDF minimizes the risk of neglecting important factors that may not be obvious at the outset of study design. The TDF can also guide the design and development process for future KT efforts. In addition, the current study included all three physician groups who manage MIBC; this allowed us to capture each group's unique cultures, beliefs and practices.
The low overall response and selection bias may limit the generalizability of the results. The fact that 9/10 urologists referred patients for chemotherapy also suggests that the study respondents likely represent a sub-group of practitioners who have already adopted NACT. Further, due to the small sample size our statistical power was limited for the conduct of multivariable analyses. Another limitation is that our study did not consider barriers/enablers to use of NACT/ACT from the patient perspective; this will form a parallel line of inquiry in the future. Finally, in an effort to quantify the association between TDF domains and use/referral of chemotherapy we used a pooled mean score approach across all questions within a specific domain. Pooling data across related questions in one domain may obscure a particularly strong barrier/enabler that was identified in a single question; to mitigate this we also carefully evaluated free-text responses regarding the greatest challenges/successes at their centre.
Interventions that have been designed to improve the uptake of research evidence into clinical practice in other disease settings have had limited and varied effects [23] . This may relate to a lack of explicit rationale for the intervention choice [16, 24] . Using a validated theoretical framework at the outset helped to ensure that our study design, conduct, and interpretation would optimize the design of a future intervention study [16, 17] . The TDF allowed us to identify barriers/enablers within each domain can be now guide selection of the most appropriate KT intervention [25, 26] . For example, in the current study negative beliefs about the consequences of referral to MO for chemotherapy consultation by urologists may be modified by using influential peer opinion leaders at local sites or provision of information regarding patient outcomes. Finally, environmental changes to facilitate behavior change including the implementation of institutional policy mandating multidisciplinary collaboration may be required.
A four-step systematic approach for the development of theory-based behavioural change interventions has been described in the literature [16] . Our previous work has addressed step 1 of this process, revealing both low patterns of referral from urologists to MOs for NACT/ACT and low use of chemotherapy by MOs [6, 7] . The current study addresses step 2, identification of key barriers and enablers to the use of NACT/ACT among patients with bladder cancer. Steps 3 and 4 involve identifying, implementing, and measuring the impact of appropriate behavior change techniques; this represents a logical evolution of our research program.
In summary our study suggests that local urology and MO champions ('social and professional role') who advocate for NACT/ACT, systems-level factors ('environmental context/resources') that optimize multidisciplinary care, and patient engagement ('social influences') in the discussion of treatment options are critical factors that need to be considered in any future efforts to improve utilization of chemotherapy for MIBC. Our data also demonstrate a large gap between outcomes anticipated by clinicians and outcomes observed in routine practice. This has important implications for clinicians counselling patients regarding prognosis and treatment options. Findings from this study will be useful to policy and decision makers in the research planning, implementation and evaluation process. 
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